CBD /

 

Loading...
Living Modified Organism (LMO)
  |  
BCH-LMO-SCBD-115064-1   |   PDF   |   Print   |  
| 
|  Close
Decisions on the LMO Risk Assessments  
last updated: 25 Jul 2019
Living Modified Organism identity
The image below identifies the LMO through its unique identifier, trade name and a link to this page of the BCH. Click on it to download a larger image on your computer. For help on how to use it go to the LMO quick-links page.
VECTORMUNE® ND
EN
HVT-F/NDV
No
VECTORMUNE® ND is vaccine against Newcastle disease (ND) and Marek's Disease (MD). The vaccine contains modified Turkey Herpesvirus (Marek's disease vaccine; serotype 3), expressing fusion protein from Newcastle disease virus.
EN
The term “Recipient organism” refers to an organism (either already modified or non-modified) that was subjected to genetic modification, whereas “Parental organisms” refers to those that were involved in cross breeding or cell fusion.
Turkey Herpesvirus serotype 3
EN
  • BCH-LMO-SCBD-114750-3
    VECTORMUNE® HVT-NDV + Rispens
    | Ceva Saude Animal Ltda (CEVA) | Production of medical or pharmaceutical compounds (human or animal) (Vaccines)
Characteristics of the modification process
p45/p46PecF
EN
  • Virus-mediated gene transfer
 
0.280 kb
 
 
0.270 kb
 
 
1.660 kb
 
 
0.326 kb
 
Some of these genetic elements may be present as fragments or truncated forms. Please see notes below, where applicable.
  • BCH-GENE-SCBD-105090-4 Fusion protein gene | Avian orthoavulavirus 1 (Newcastle disease virus, NDV)
    Protein coding sequence | Production of medical or pharmaceutical compounds (human or animal) (Vaccines)
  • BCH-GENE-SCBD-114749-2 CMV Early Enhancer | Human betaherpesvirus 5 (Human cytomegalovirus, HCMV, HHV-5)
    Enhancer
  • BCH-GENE-SCBD-105217-2 Beta-actin gene promoter | Gallus gallus (Chicken, CHICK)
    Promoter
  • BCH-GENE-SCBD-114748-3 SV40 poly-adenylation signal | Macaca mulatta polyomavirus 1 (SV40, Simian vacuolating virus 40, simian virus 40, Rhesus macaque polyomavirus)
    Terminator
The recombinant virus contains an expression cassette located in the intergenic region between genes UL45 and UL46 Turkey Herpesvirus (HVT). The recombinant virus was created by transfecting chick embryo fibroblast cells with wild-type HVT strain FC126 and the plasmid vector p45/46PecF. During viral packaging, recombination of the genetic material occurred due to the homologous sequences of UL45 and UL46 flanking the expression cassette in the plasmid vector and recombinant viruses were produced.

During viral transcription, the Cytomegalovirus enhancer promotes strong transcription from the chicken (Gallus gallus) beta-actin promoter and transcribes the Newcastle disease virus fusion protein (Protein F) before terminating at the Macaca mulatta polyomavirus 1 poly-adenylation signal.

The recombinant virus is sufficient to create immunity to Newcastle disease virus and Merek's disease virus (Gallid alphaherpesvirus 2).
EN
LMO characteristics
EN
  • Vaccine
Detection method(s)
Protein Detection:
The expression of NDV Protein F was confirmed using Southern blotting.
EN
Additional Information
EN

Quick links

About the BCH About the Cartagena Protocol Supplementary Protocol

Sign in Search records Submit records
Registries: LMO-Organism-Gene Country Profiles
National Report Analyzer

Forums BCH Announcements

Need help?

Knowledge Base FAQs UNEP eLearning Training Site

Contact us at: bch@cbd.int
BCH Biosafety Clearing-House
Subscribe to e-mail notifications
Subscribe to our newsletter